^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    GT 316

    i
    Other names: GT 316, GT316
    Associations

    News

    Trials
    Company:
    Grit Biotechnology
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    1year
    Clinical Study of Autologous Tumor Infiltrating Lymphocyte Injection (GT316) in the Treatment of Advanced Solid Tumors (Gynecological Tumors) (clinicaltrials.gov)
    P=N/A, N=36, Recruiting, Grit Biotechnology
    New trial
    |
    GT 316
    1year
    Autologous Tumor Infiltrating Lymphocyte Injection for the Treatment of Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=30, Recruiting, Grit Biotechnology
    New P1 trial • Metastases
    |
    GT 316
    almost2years
    The discovery and development of a CRISPR/Cas9-engineered tumor-infiltrating lymphocytes product (GT316) as a next-generation TIL therapy (AACR 2023)
    In summary, these data demonstrated that our ImmuT Finder® platform enables unbiased discovery of potent and novel targets for the development of T cell therapy and support the clinical assessment of GT316 as a next-generation TIL therapy. Currently, an investigator-initiated trial of GT316 is ongoing in China.
    Tumor-infiltrating lymphocyte
    |
    IL2 (Interleukin 2)
    |
    GT 316